Recent Updates
Recently added Catalysts
MDWD Positive Sentiment Score: 75/100

MediWound to Present at Upcoming Investor Conferences

Tuesday, February 17, 2026 1 min read
Key Takeaway: MediWound Ltd. will present at two upcoming investor conferences, the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TDCowen 46th Annual Health Care Conference. The presentations will showcase the company's advancements in enzymatic therapeutics for tissue repair, including their FDA-approved product NexoBrid and the investigational therapy EscharEx. Webcasts of the presentations will be available for interested parties.
Price reaction · baseline $17.27 (2026-02-13 close) · hit pre-market · 1 other MDWD headline(s) in the window, move may be shared
day 0 close · peak
+2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • MediWound is actively engaging with investors through multiple conferences.
  • The company is recognized as a leader in enzymatic therapeutics for tissue repair.
  • MediWound's FDA-approved product, NexoBrid, is already marketed in several regions.
  • The investigational therapy, EscharEx, has potential to set a new standard in wound management.

Full Press Release Details

MediWoundto Present at Upcoming Investor Conferences
YAVNE, Israel,February17,2026--MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair,todayannouncedthat itsmanagementteamwill present atthe followingupcoming investor conferences:
Oppenheimer 36th Annual Healthcare Life Sciences Conference
Date:Thursday,February 26, 2026
Time:10:40 a.m.ET
Location: Virtual
Webcast:Available via conference website
TDCowen 46th Annual Health Care Conference
Date:Monday, March 2, 2026
Time:1:10 p.m.ET
Location: Boston Marriott Copley Place, Boston, MA
Webcast:Available via conference website
A live webcast and replay of each presentation will be accessible through theEvents & Presentationssection of the Investor Relations area of MediWound’s website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.
For more information, visitwww.mediwound.comand follow us onLinkedInandX (formerly Twitter).
MediWound Contacts:
Hani LuxenburgChief Financial OfficerMediWound Ltd.ir@mediwound.com Daniel FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com

Frequently Asked Questions

When will MediWound present at the Oppenheimer conference?

MediWound will present at the Oppenheimer conference on February 26, 2026, at 10:40 a.m. ET.

Where is the TDCowen conference being held?

The TDCowen conference will take place at the Boston Marriott Copley Place in Boston, MA.

What is NexoBrid used for?

NexoBrid is an FDA-approved biologic for the enzymatic removal of eschar in thermal burns.

What is EscharEx?

EscharEx is an investigational therapy aimed at the debridement of chronic wounds.

Tags: MDWD Viatris Investor Conferences Healthcare MediWound NexoBrid EscharEx investor conference
Last updated: Feb 17, 2026

Biotech snapshot

Lead asset
EscharExPhase 3
Venous Leg Ulcer (VLU) →

Catalyst track record

+27%
best trade around MDWD's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for MDWD.

See every catalyst's timing & PoA →